Phosphodiesterase 5 inhibitors in vascular systemic disorders

被引：4
|
作者：
Allanore, Yannick [1 ]
机构：
[1] Univ Paris 05, INSERM U1016, Serv Rhumatol, Hop Cochin, F-75014 Paris, France
来源：
JOINT BONE SPINE | 2012年 / 79卷 / 04期
关键词：
Phosphodiesterase; Nitric oxide; Pulmonary hypertension; Raynaud's phenomenon; Sildenafil; Tadalafil; PULMONARY ARTERIAL-HYPERTENSION; RAYNAUDS-PHENOMENON RESISTANT; DOUBLE-BLIND; SILDENAFIL; THERAPY; TADALAFIL; SCLEROSIS; EFFICACY;
D O I：
10.1016/j.jbspin.2011.12.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：338 / 340
页数：3
相关论文
共 50 条
  • [31] PHOSPHODIESTERASE ISOZYME INHIBITORS AND VASCULAR SMOOTH-MUSCLE
    SILVER, PJ
    HARRIS, AL
    EVANS, DB
    BLOOD VESSELS, 1988, 25 (01): : 49 - 50
  • [32] Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue
    Antinozzi, Cristina
    Sgro, Paolo
    Di Luigi, Luigi
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2020, 2020
  • [33] Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders
    Samidurai, Arun
    Xi, Lei
    Das, Anindita
    Kukreja, Rakesh C.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2023, 63 : 585 - 615
  • [34] Phosphodiesterase 10 inhibitors in clinical development for CNS disorders
    Geerts, Hugo
    Spiros, Athan
    Roberts, Patrick
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2017, 17 (06) : 553 - 560
  • [35] From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity
    Abdel-Halim, Mohammad
    Sigler, Sara
    Racheed, Nora A. S.
    Hefnawy, Amr
    Fathalla, Reem K.
    Hammam, Mennatallah A.
    Maher, Ahmed
    Maxuitenko, Yulia
    Keeton, Adam B.
    Hartmann, Rolf W.
    Engel, Matthias
    Piazza, Gary A.
    Abadi, Ashraf H.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (08) : 4462 - 4477
  • [36] PHOSPHODIESTERASE-5 INHIBITORS IN MEN WITH HIV
    Dinsmore, W.
    Mccarty, E.
    JOURNAL OF SEXUAL MEDICINE, 2011, 8 : 87 - 87
  • [37] Phosphodiesterase Type 5 Inhibitors, Sport and Doping
    Di Luigi, Luigi
    Sansone, Massimiliano
    Sansone, Andrea
    Ceci, Roberta
    Duranti, Guglielmo
    Borrione, Paolo
    Crescioli, Clara
    Sgro, Paolo
    Sabatini, Stefania
    CURRENT SPORTS MEDICINE REPORTS, 2017, 16 (06) : 443 - 447
  • [38] Recreational use and misuse of phosphodiesterase 5 inhibitors
    Smith, KM
    Romanelli, F
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2005, 45 (01) : 63 - 75
  • [39] Novel indications for phosphodiesterase type 5 inhibitors
    Rosenkranz, Stephan
    Caglayan, Evren
    Erdmann, Erland
    MEDIZINISCHE KLINIK, 2007, 102 (08) : 617 - 630
  • [40] Phosphodiesterase 5 inhibitors in male sexual dysfunction
    Kuthe, A
    CURRENT OPINION IN UROLOGY, 2003, 13 (05) : 405 - 410
12345